| |
U-M scientists receive $7.28M in Life Sciences Corridor funding
By Karl Leif Bates
Life Sciences Institute
Four U-M research teams received $7.28 million of funding from the Michigan Life Sciences Corridor in grants announced May 28 by the state of
Michigan. This year the corridor awarded grants totaling $30 million allocated from the state's tobacco settlement money to encourage life sciences product
development and economic growth in Michigan.
The U-M projects will tackle some of the biggest health problems in the state, including cancer, kidney disease and disorders of the blood vessels in
the brain.
Trojan horse drug delivery
James R. Baker Jr., the Ruth Dow Doan Professor
of Biologic Nanotechnology and chief of allergy and clinical immunology
in the Medical School, leads a team that will receive $1.3 million to
develop a tiny drug delivery platform that invades a cancer cell and poisons
it from the inside. The polymer nanodevices target a drug to a specific
tissue, reducing side effects that occur when a drug hits the wrong kind
of cell. Each tiny particle is studded with molecules that bind to the
surface of specific cells, in this case tumor cells. The particle and
the drug it carries are then internalized in the cell, where the platform
partially dissolves, releasing the drug. "You get much more effective
and specific killing of the cancer cells delivering medications this way,"
Baker says.
Earlier detection of the deadliest cancer
Craig Logsdon, professor of physiology
and a member of the Comprehensive Cancer Center, is leading a $2.4 million
effort to develop a blood test for pancreatic cancer, which has the worst
five-year survival rate of any cancer. As with all cancers, early detection
is the key to survival, but pancreatic cancer is notoriously difficult
to diagnose in time to save the patient. A test for marker proteins unique
to pancreatic cancer might enable doctors to make the diagnosis sooner.
The goal is to identify some characteristic molecules that indicate cancerous
pancreatic cells. "Discovery of molecules expressed in pancreatic
cancer may also lead to new treatments for this deadly disease,"
Logsdon says.
Stem cell therapy for kidney disease
H. David Humes, professor of internal medicine
at the Medical School, will use a $1.4 million corridor grant to test
a new therapy for patients with kidney failure who use dialysis to clean
their blood at least three times a week. These chronic dialysis patients
often experience fatal complications that are related to inflammation.
Humes believes the problem may be an absence in the patients' damaged
kidneys of tubule cells, which normally keep inflammation in check. Using
an outside-the-body device he developed, which processes blood through
a tube containing living kidney cells, Humes hopes to replace the function
of tubule cells to these patients and forestall the development of inflammatory
complications.
Fighting brain lesions with a natural plastic
Daryl Kipke, associate professor and director
of the Neural Engineering Laboratory in the Department of Biomedical Engineering,
received a $2.21 million grant to further develop a material that can
be injected through microcatheters to stabilize malformed blood vessels
in the brain, making them safer and easier to treat surgically. These
brain vascular lesions, including aneurysms, can be hardened to a "soft
gel consistency" with the injection of a seaweed-based polymer Kipke's
lab has developed. ALGEL is biologically benign and eventually might be
used to fill or plug up blood vessels without triggering an immune response,
Kipke says.
Corridor funding also was granted to two U-M labs that provide core technology
to researchers throughout the state. The Michigan Proteome Consortium,
led by U-M biological chemistry professor Phil
Andrews, received $2.1 million. The Michigan Center for Biological
Information, headed by assistant professor of cell and developmental biology
Brian Athey, received $1.6 million.
More stories
|
|